61
Participants
Start Date
March 31, 2015
Primary Completion Date
December 5, 2019
Study Completion Date
December 5, 2019
MK-3475
Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
Bevacizumab
Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
MK-3475
Arm B: Phase II Treatment: 200mg IV
Bevacizumab
Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
Penn State Hershey Cancer Institute, Hershey
University of Michigan Comprehensive Cancer Center, Ann Arbor
Michigan State University, Breslin Cancer Center, Lansing
University of Iowa, Holden Comprehensive Cancer Center, Iowa City
University of Minnesota: Masonic Cancer Center, Minneapolis
Northwestern University, Robert H. Lurie Cancer Center, Chicago
University of Illinois Cancer Center, Chicago
University of Nebraska, Fred and Pamela Buffet Cancer Center, Omaha
Rutgers Cancer Institute of New Jersey, New Brunswick
Merck Sharp & Dohme LLC
INDUSTRY
Big Ten Cancer Research Consortium
OTHER
Arkadiusz Z. Dudek, MD
OTHER